Details for Patent: 8,148,401

« Back to Dashboard

Which drugs does patent 8,148,401 protect, and when does it expire?

Patent 8,148,401 protects DAURISMO and is included in one NDA.

This patent has fifty-nine patent family members in forty-seven countries.

Summary for Patent: 8,148,401

Title:	Benzimidazole derivatives
Abstract:	The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
Inventor(s):	Michael J. Munchhof, Lawrence A. Reiter, Susan D. La Greca, Christopher S. Jones, Qifang Li
Assignee:	Pfizer Corp SRL
Application Number:	US12/142,119
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,148,401

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	DAURISMO	glasdegib maleate	TABLET;ORAL	210656-001	Nov 21, 2018		RX	Yes	No	8,148,401		Y	Y
Pfizer	DAURISMO	glasdegib maleate	TABLET;ORAL	210656-002	Nov 21, 2018		RX	Yes	Yes	8,148,401		Y	Y

International Family Members for US Patent 8,148,401

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2170860		301057	Netherlands
European Patent Office	2170860		LUC00173	Luxembourg
European Patent Office	2170860		132020000000109	Italy
European Patent Office	2170860		PA2020528	Lithuania
European Patent Office	2170860		2020C/530	Belgium